Jefferies has upgraded Vertex Pharmaceuticals Inc. (NASDAQ ... which includes treatments for chronic pain and APOL1 kidney disease. The analyst increased the price target from $500 to $550.

Vertex’s pain treatment and kidney disease programs are seen as significant growth drivers. Jefferies has upgraded Vertex Pharmaceuticals Inc. VRTX, citing the company’s robust cystic fibrosis ...

Jefferies has upgraded Vertex Pharmaceuticals Inc. (NASDAQ ... which includes treatments for chronic pain and APOL1 kidney disease. The analyst increased the price target from $500 to $550. A recent ...

In this article, we are going to take a look at where Vertex Pharmaceuticals ... currently spans 5 disease verticals: sickle cell/beta thalassemia, type 1 diabetes, APOL-1 kidney disease, IgA ...

On Thursday, Vertex Pharmaceuticals Incorporated (NASDAQ ... Also Read: Vertex Has $5 Billion-Plus Opportunity In Pain And Kidney Disease Programs, Analyst Upgrades Stock The study also included a ...

In the last three months, 19 analysts have published ratings on Vertex Pharmaceuticals VRTX ... therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small ...

The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals ... with a type of kidney disease, the health regulator's website showed on Wednesday. Vertex Pharmaceuticals raised ...

To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals ... APOL1-mediated kidney disease, IgA nephropathy, primary ...